Proactive Investors - Run By Investors For Investors

VolitionRx well funded as it advances development of its novel cancer tests

VolitionRx Limited (NYSEAmerican:VNRX) CEO Cameron Reynolds brings Proactive's Andrew Scott up to date on developments with their cancer blood tests as well as discussing the group's 2018 results.

As of the end of December, Volition's cash position stood at $13.4 million - up from $10.1 million at the close of 2017.

Reynolds says continued development of their Nu.Q Capture and Nu.Q Vet products coupled with the strengthening of the company's product pipeline beyond colorectal cancer will help them generate early revenue.

View full VNRX profile View Profile

VolitionRx Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use